ADAM ZUBER: Open Payments
NPI 1144895574 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,326 in 179 payments from 18 companies in 2025. Trend: 2023 $3,426 · 2024 $3,277 · 2025 $3,326
Food & beverage: $3,241Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 79 | $1,073 |
| Janssen Biotech, Inc. | 39 | $885 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $296 |
| Gilead Sciences, Inc. | 10 | $156 |
| GENZYME CORPORATION | 5 | $141 |
| Enterra Medical, Inc. | 1 | $99 |
| Aimmune Therapeutics, Inc. | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $92 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $86 |
| Ardelyx, Inc. | 4 | $75 |
Products named: TREMFYA, RINVOQ, DUPIXENT, ENTYVIO, MAVYRET, LINZESS, CREON, SKYRIZI.
Industry payments across IN — which companies pay providers there.
